developing mammalian neural stem cells, 8 epilepsy 9 and human germ cells progression. 10 However, the roles and targets of PUM2 in cancer progression are still unclear. Here, we found that PUM2 expression was significantly decreased in OS tissues, and assumed that PUM2
held inhibitory effects in OS progression.
miRNAs could regulate transcripts expression via directly binding to mRNAs 3′UTR and thus inhibit their expression, or promote their degradation. 11 Importantly, miRNAs play critical roles in cancer progression, like in tumour angiogenesis, 12 metastasis, 13 apoptosis, 14 and drug resistance. 15 Previous studies have shown that RBPs could competitively bind to mRNAs 3′UTR via miRNAs, for example, transformer 2beta and miR-204 could regulate apoptosis through competitively binding to 3′UTR of BCL2 mRNA. 16 The RBP ARPP21 could control dendritic branching by functionally opposing the miRNA it hosts. 17 These studies demonstrate that RBPs and miRNAs could co-regulate transcripts expression collectively.
STARD13 (StAR-related lipid transfer domain 13) has been confirmed to hold suppressive roles in various tumour progression, like
Li et al and Hanna et al have shown that STARD13 inhibits breast
cancer metastasis. 18 , 19 Guo et al 20 
have indicated that STARD13
3′UTR could promote breast cancer apoptosis and Zhang et al 21 have demonstrated that STARD13 promotes hepatocellular carcinoma apoptosis by acting as a ceRNA for Fas. However, the roles of STARD13 3′UTR and related mechanisms by which STARD13 is regulated in OS progression are still unclear.
In the present study, we showed that RBP PUM2 and STARD13 expression was significantly decreased in OS tissues compared with that in normal adjacent tissues, and exhibited positive correlation in OS tissues. Furthermore, we identified that PUM2 directly and competitively bound to STARD13 3′UTR with miR-590-3p and miR-9. Additionally, PUM2 and STARD13 3′UTR inhibited OS cells migration, proliferation, and stemness, and PUM2 exerted its effects in a STARD13 3′UTR-and miRNAs-dependent manner. Importantly, overexpression of STARD13 3′UTR could inactivate RhoA/Rock pathway. Thus, our results indicate that RBP PUM2 could suppress
OS progression via directly and competitively binding to STARD13
3′UTR with related miRNAs, and thus inhibiting RhoA/Rock pathway. foetal bovine serum (Gibco), 80 U/mL penicillin, and 0.08 mg/mL streptomycin at 37°C under humidified atmosphere with 5% CO 2 . 
| MATERIAL SANDME THODS

| Clinicalsamplesandcellsculture
| Real-timequantitativePCR
| RNAimmunoprecipitation
The detailed procedure was denoted in our previous work. 7 Briefly, 
| Transcriptssequencinganddataanalysis
We thanked Novengene Co. Ltd (Beijing, China) for conducting this experiment and analysing data. Total RNA extracted from three OS and normal adjacent tissues, and RNA immunoprecipitation (RIP)
were used for RNA-seq. RNA-seq libraries were acquired using 
| Lentiviruspackageandstableexpressioncell linesconstruction
The detailed procedure was mentioned in our previous work. 7 PUM2
overexpression (Lenti-PUM2), PUM2 knockdown (Lenti-PUM2-shRNA), STARD13 3′UTR overexpression (Lenti-S-UTR), RhoA overexpression (Lenti-RhoA), and control virus plasmids were packaged.
Afterwards, virus with 2 μg/mL polybrene was added into OS cells for 72 hours and infected cells were selected with puromycin (Sigma; 2 μg/ mL) for 2 weeks, followed by RT-qPCR and western blot verification. 
| Westernblot
| Cellproliferationassay
Cell Counting Kit-8 (CCK8; Beyotime) was used to evaluate cell pro- 
| Cellmigrationassay
The detailed procedure was reported in the previous study. 
| ALDH1activityassay
ALDH1 activity was assayed by ALDH Activity Assay Kit (Colorimetric) (Cat # KA3742; Abnova, San Diego, CA, USA) according to the manufacturer's protocols.
| Transfection
Cells were seeded at plates. When cells were grown to 80% density, 
| Luciferasereporterassay
Luciferase reporter analysis was performed to examine the binding of PUM2 and miRNAs (miR-590-3p, miR-9, miR-653, and miR-182) on STARD13 3′UTR. The sequence of STARD13 promoter, 5′UTR, coding area or 3′UTR was cloned into PMIR-Reporter plasmid, respectively, named as Luc-S-P, Luc-S-5′UTR, Luc-S-CDS, and Luc-S-3′UTR.
Then these above plasmids were cotransfected with Lenti-PUM2
infection in OS cells, or with miRNA mimics or inhibitors, or NC into OS cells with β-gal (Ambion, Grand Island, NY, USA) plasmid using
Lipofectamine 2000 for 72 hours. After that, the luciferase activity of Luc-S-UTR was measured using a Luciferase Reporter Assay Kit (cat. no. K801-200; BioVision, Inc., Milpitas, CA, USA). β-gal activity was determined using a β-Galactosidase Enzyme Assay System with Reporter Lysis Buffer (cat. no. E2000; Promega Corporation,
Madison, WI, USA) following the manufacturer's protocols, which was used as a normalization control for luciferase activity.
| RhoAGTPaseassay
RhoA GTPase activity was analysed by RhoA G-LISA (Cat # BK132;
Cytoskeleton, Denver, CO, USA) following the manufacturer's protocol. Briefly, cells were lysed and protein concentration was measured. Lysis buffer was added to equalize the cell extracts to
give identical protein concentrations in each sample. Samples were handled following the technical guide. Finally, absorbance at 490 nm was measured using a microplate spectrophotometer to reflect the RhoA GTPase activity shown as relative value.
| F-actinvisualization
F-actin was stained with rhodamine phalloidin (Cat BK005;
Cytoskeleton) for 30 minutes at room temperature following the manufacturer's protocol. The nuclei was stained by DAPI (C1002; Beyotime) for 10 minutes and observed with the confocal microscopy. Images were analysed using OLYMPUS FLUOVIEW ver.3.0
Viewer software.
| Invivotumorigenicassay
Male athymic BALB/c nude mice (4-6 week) were purchased from
Model Animal Research Center of Nanjing University, housed and fed in standard pathogen-free conditions. For tumour-limiting dilution assays, tumour cells were mixed 1:1 with matrigel matrix (BD Biosciences, Franklin Lakes, NJ, USA) and subcutaneously implanted in the mice. On day 8, all mice were killed and tumour tissues were collected and weighed. All animal studies were approved by the Shanghai JiaoTong University Animal Care and Use Committee.
| Statisticalanalysis
All data were obtained from at least three independent experiments, and presented as the mean ± standard deviation. Data sets with only two groups were analysed using a Student's t-test.
Differences between multiple groups were analysed using oneway analysis of variance with the Tukey-Kramer post hoc test.
P < 0.05 was considered to indicate a statistically significant difference.
| RE SULTS
| RBPPUM2expressionissignificantly decreasedinOStissuesandpositivelycorrelatedwith themetastasisfreesurvivalofOSpatients
Firstly, total RNA from OS and normal adjacent tissues were subjected to RNA sequencing, and we found that total 73 genes were upregulated in OS tissues and 80 genes were downregulated. Then we focused on RBPs which were listed in starBase v2.0 (http:// starbase.sysu.edu.cn/rbpMrna.php), and significantly decreased in OS tissues. As shown in Figure 1A , several RBPs expression was significantly decreased in OS tissues. RT-qPCR analysis was further performed to confirm the change of these RBPs expression, and we found that the change of RBP PUM2 expression was the most significant ( Figure 1B) . Additionally, western blot assay confirmed that PUM2 expression was remarkably decreased in OS tissues ( Figure 1C ). Importantly, KM-Plotter assay from online TCGA data set (http://hgserver1.amc.nl/cgi-bin/r2/main.cgi) which included 127 OS tissues showed that PUM2 expression was positively correlated with the metastasis-free survival of OS patients ( Figure 1D ). Thus, PUM2 was chosen for the following research.
| OverexpressionofPUM2inhibitsOScells proliferationandmigration
We further detected PUM2 expression in various OS cell lines, and found that PUM2 expression was significantly decreased in MG63 and 
| OverexpressionofPUM2inhibitsOS cellsstemness
As tumour cells stemness could lead to tumours recurrence and chemoresistance, 24, 25 we further investigated whether PUM2 could suppress OS cells stemness. Firstly, we found that overexpression of PUM2 inhibited the expression tumour stemness markers (Nanog and ALDH1) ( Figure 3A-C) . Meanwhile, cell spheroid formation was remarkably attenuated by PUM2 overexpression in OS cells characterized as 
| OverexpressionofPUM2inhibitsOScells progressioninvivo
We continue exploring whether PUM2 regulates tumour-initiating potential of OS cells in vivo. We compared the capacity of PUM2- 
| OverexpressionofPUM2increasesSTARD13 expressionviadirectlybindingtoSTARD133′UTR
Since PUM2 belongs to RBPs which have their targets, we tried to search the potential targets of PUM2 in OS cells. Bioinformatics 
F I G U R E 2 Overexpression of PUM2 inhibits OS cells proliferation and migration. (A) PUM2 expression was detected in OS cell lines (MG63, U2OS, Saos2, and 143B). (B, C) The infected efficiency of Lenti-PUM2 was confirmed in MG63 and Saos2 cells via RT-qPCR (B) and western blot (C) analysis. (D, E) Cell viability of MG63 and Saos2 cells with PUM2 overexpression or not was determined by CCK8 assay. (F, G) The ability of cell migration was examined in cell depicted in (D) and quantified (G). (H, I) The expression of EMT makers (E-cadherin and Vimentin) was evaluated in cells depicted in (D) via RT-qPCR (H) and
F I G U R E 3 Overexpression of PUM2 inhibits OS cells stemness. (A, B) ALDH1 (A) and Nanog (B) mRNA level was detected in OS cells with PUM2 overexpression or not. (C) ALDH1 and Nanog protein level was evaluated in OS cells depicted in (A). (D, E) The mammospheres size (D) and numbers (E) were examined in cells depicted in (A). (F) ALDH1 activity was measured in cells depicted in (A). Data were
presented as the mean ± SD; *P < 0.05 vs control Figure 5D ,E). In particular, STARD13 promoter activity was unaffected in PUM2 knockdown cells ( Figure 5F ), indicating that PUM2 could not affect STARD13 promoter activity.
Importantly, further luciferase reporter assays with Luc-S-5′UTR,
Luc-S-CDS, or Luc-S-3′UTR transfection, respectively, as well as
Lenti-PUM2 infection, indicated that PUM2 overexpression just increased the activity of Luc-S-3′UTR, but unaffected the activity of Luc-S-5′UTR or Luc-S-CDS ( Figure 5G ). Furthermore, RIP assays with RT-qPCR primers expanding STARD13 3′UTR showed that PUM2 could interact with STRAD13 3′UTR directly in OS cells ( Figure 5H ). These results indicated that PUM2 could directly bind to STRAD13 3′UTR, and thus enhance STARD13 mRNA stability and expression.
| PUM2exertsitsinhibitoryeffectsdependent onSTARD133′UTR
We further investigated the detailed binding sites of PUM2 and whether PUM2 exerted its inhibitory effects via STARD13 3′UTR. . RT-qPCR was used to measure the abundance of STARD13 mRNA that was present in the PUM2-IP materials after the RIP assay. Data were presented as the mean ± SD; *P < 0.05 vs control proliferation, migration, and stemness ( Figure S1 ). Then we performed genome-wide RIP-seq analysis to identify the PUM2-bound mRNA regions with antibody against PUM2. Peak and motif analysis revealed that the 5′-UAA-3′ motif was discovered to be highly enriched (P = 1e −8 ) ( Figure 6A ). Furthermore, PUM2 knockdown was then performed with Lenti-PUM2-shRNA infection in U2OS cells which has been shown to hold relative high expression level of PUM2. As shown in Figure 6B ,C, Lenti-PUM2-shRNA infection significantly downregulated PUM2 and STARD13 expression. 
| OverexpressionofPUM2competitivelybound toSTARD133′UTRwithmiR-590-3pandmiR-9
Since miRNAs could bind to mRNA 3′UTR, miRNA.org (www.miRNA.
org) predicted that various miRNAs could bind to STARD13 3′UTR, and we searched the miRNAs that could bind to 5′-UAA-3′ motif and found that miR-590-3p, miR-9, miR-653, and miR-182 could bind to STARD13 3′UTR containing 5′-UAA-3′ motif ( Figure 7A ). Notably, . Data were presented as the mean ± SD; *P < 0.05 vs control miR-9 had been proved to bind to STARD13 3′UTR in breast cancer in previous study. 18 Luciferase reporter analysis indicated that miR-590-3p and miR-9 mimics or inhibitors significantly decreased or increased the activity of Luc-S-3′UTR, respectively, but miR-653
and miR-182 could not ( Figure 7B ), indicating that STARD13 was a potential target of miR-590-3p and miR-9 but not miR-653 and miR-182. To confirm the direct interaction between miR-590-3p, miR-9 and STARD13 at endogenous levels, we performed RIP analysis to pull down endogenous miRNAs associated with Ago2
in Luc-S-3′UTR-overexpressed MG63 cells. The precipitated miRNAs were subjected to RT-qPCR analysis and results showed that miR-590-3p and miR-9 were enriched in RNAs retrieved from Luc-S-3′UTR-overexpressed cells ( Figure 7C ). Furthermore, RT-qPCR and western blot assay indicated that STARD13 expression was inhibited or promoted by miR-590-3p or miR-9 mimics, or inhibitors, respectively ( Figure 7D ,E), supporting that STRAD13 was the bona fide target of miR-9 and miR-590-3p in OS cells. Next, we assumed that PUM2 could competitively bind to STARD13 3′UTR with miR-590-3p and miR-9. As expected, the promotion of PUM2 overexpression on STARD13 expression was attenuated by miR-590-3p or miR-9 overexpression ( Figure 7F,G) . Importantly, the inhibition of PUM2 on OS cells progression was rescued by miR-590-3p or miR-9 overexpression too ( Figure S2 ). Therefore, our results suggest that PUM2 could suppress OS cells progression via competitively binding to STARD13 3′UTR with miR-590-3p and miR-9.
| OverexpressionofPUM2inhibitsOScells progressionviasuppressingRhoA/Rockpathway
Finally, we tried to explore the downstream signalling of PUM2/ STARD13 3′UTR axis. Previous studies have identified that STARD13 could block RhoA-ROCK signalling axis by acting as a
RhoGTPase-activating proteins (GAP) 26 and thus disorganizing Factin structure and RhoA-ROCK signalling could contribute to tumour stemnes. 27 Firstly, we detected whether STARD13 3′UTR 
| D ISCUSS I ON
OS is a primary malignancy that is most common in adolescents; although the survival of OS patients is significantly upregulated with adjuvant chemotherapy and surgery, metastasis and chemoresistance represent a clinical challenge for OS. 28 Hence, it is important to elucidate the mechanisms and find novel targets for facilitating OS treatment.
In the present study, we identified that RBP PUM2 expression was significantly decreased in OS tissues, and inhibited OS cells proliferation, migration, and stemness. To the best of our knowledge, this is the first study showing the roles of PUM2 in OS progression. Further RIP-seq and RNA sequencing were used to identify the potential targets of PUM2, and STARD13 was identified as a direct target of PUM2. Importantly, the 5′-UAA-3′ motif in STARD13 3′UTR was determined as the binding sites of PUM2.
mRNA stabilization is regulated by RBPs and miRNAs; miRNAs associate with the RNA-induced silencing complex (RISC) and recognize target mRNAs containing 3′UTRs with partially complementary sequence. 15 RBPs influence mRNA stability and translation by interacting mainly with the 3′UTR. 6 Here, we found that the binding sites of PUM2 were overlapped with the binding sites of miR-590-3p and miR-9, and PUM2 regulated STARD13 expression via competitively binding with these two miRNAs. Notably, STARD13 has been identified as the target of miR-9 in previous reports in breast cancer. 18, 29 This suggests that miR-9/STARD13 might be a common regulatory axis in tumours. Several stud- Here, we confirmed that PUM2 could antagonize miR-590-3p and miR-9 functions on STARD13 expression.
By informatics methods analysis, PUM2 was predicted to have other targets, indicating that PUM2 likely has wide-ranging roles in gene expression, and the regulatory mechanism for STARD12 expression may be more complex than simply competitive interaction between PUM2 and miR-590-3p and miR-9. However, the competitive interaction between PUM2 and miR-590-3p, and miR-9 may provide new insight into the regulation of STARD13 expression in OS cells. Since STARD13 has been identified as a tumour suppressor in other cancers, [18] [19] [20] [21] 26 we are wondering whether PUM2/STARD13 3′UTR regulatory axis is a common phenomenon in other tumours; this could be explored in the future studies.
In sum, we showed that PUM2/STARD13 3′UTR regulatory axis could suppress OS cells progression through RhoA/Rock signalling.
Despite more details need to be elucidated, we proposed that drugs promoting PUM2/STARD13 3′UTR regulatory axis might target OS and could be used as a combinative treatment with chemotherapy in OS therapy. 
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